on ABIVAX (EPA:ABVX)
Abivax to Hold Expert Webcast on Ulcerative Colitis
Abivax, a biotechnology company specializing in treatments for chronic inflammatory diseases, announced an upcoming webcast event scheduled for March 17, 2025. This session will focus on the treatment landscape for ulcerative colitis, featuring insights from renowned gastroenterologist Dr. David T. Rubin of The University of Chicago.
The event will delve into Abivax's ongoing ABTECT Phase 3 trial, which assesses the efficacy of obefazimod in adults with moderately to severely active ulcerative colitis. Attendees will gain insight into how this trial might address unmet medical needs in UC treatment.
The webcast, starting at 9:00 a.m. EDT (2:00 p.m. CET), will also include a live Q&A session with Dr. Rubin and Abivax’s management team. Interested participants can register online to access the virtual event.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news